Skip to main content

Table 3 Nerve conduction study variables. Secondary analysis

From: High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study

Nerve conduction study variables

n

W0

W48

Relative change between W0 and W48

p-value

Motor Nerve Conduction Velocity (m/s)

15

38.5 (19.4;42.0)

35.0 (21.7;41.2)

0.6 (-7.0;7.2)

.762

Distal Motor Latency (ms)

15

6.5 (4.2;8.4)

6.1 (4.1; 8.3)

0.5 (-3.4;4.6)

.600

F Wave Latency (ms)

9

37.3 (34.5;39.3)

41.6 (34.1;46.6)

2.6 (-1.1;12.0)

.164

Duration of the Compound Muscle Action Potential (ms)

15

7.3 (5.7;9.4)

7.8 (5.8;9.7)

2.5 (-0.0;15.6)

.035

  1. Neurophysiological data considering all nerves pooled per patient – FAS population. Missing data at W48 were imputed with the LOCF method (W36 and W24 for patients #04 and #09, CIDP and CMT1 groups, respectively). The P-value was calculated with the Wilcoxon signed rank test. The results are expressed as median (IQR)
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us